I searched the Cochrane Library, MEDLINE, and Embase, supplemented by publications known to me, for articles published between 1962 and 2017. I used the search terms “atrial fibrillation” combined with “stroke prevention”, “risk factor”, “rate control”, “rhythm control”, “anticoagulation”, “combination therapy”, “stroke”, “occluder”, “ablation”, or “surgery” when required. I largely selected publications in the past 6 years on the basis of novelty, citations, and relevance for this clinical
SeminarThe future of atrial fibrillation management: integrated care and stratified therapy
Section snippets
The atrial fibrillation epidemic
Atrial fibrillation affects 2–3% of the populations in Europe,1, 2, 3 and more than 1% of Europe's health-care expenditure is spent on atrial fibrillation management.4, 5 Less than one in 200 people younger than 50 years, but more than one in ten people in populations aged 80 years or older, have atrial fibrillation.1, 2, 3 8% of the world population,6 and 13–21% of the European population are aged 65 years or older,7 and the worldwide population is living ever longer. The projected population
Clinical presentation and atrial fibrillation-associated symptoms
Atrial fibrillation is a common cause of ischaemic stroke.2 In patients with atrial fibrillation on oral anticoagulation, stroke is relatively infrequent (1·5% of anticoagulated patients with atrial fibrillation will have a stroke per year),10, 11 but worsening of heart failure and sudden death remain common even in adequately treated patients.12, 13 Common symptoms in patients with atrial fibrillation are fatigue or shortness of breath, palpitations,14, 15, 16, 17, 18, 19 anxiety,20 and a
ECG screening in populations to diagnose silent atrial fibrillation
Unfortunately, atrial fibrillation is often not diagnosed before the first stroke. About 5% of unselected patients who are admitted to stroke units present with overt (usually chronic) atrial fibrillation on admission.30 The identification of atrial fibrillation before the first stroke should therefore be a public and individual health priority. Opportunistic screening for atrial fibrillation (ie, pulse palpation followed by ECG in individuals with an irregular pulse35) is recommended by atrial
ECG screening in stroke survivors
ECG screening for silent atrial fibrillation has been extensively studied in survivors of a stroke or transient ischaemic attack. ECG monitoring for 2·5–4 days identifies silent atrial fibrillation in an additional 5% of unselected patients admitted to stroke units.30, 39 Longer ECG monitoring for a few weeks or months identifies even more patients with atrial fibrillation,30, 31, 40 especially in patients with cryptogenic stroke39, 41, 42 or embolic stroke of unknown source.43 ECG monitoring
Management of patients with atrial fibrillation identified by ECG screening
Identification of silent atrial fibrillation has immediate consequences for antithrombotic therapy. Most patients with incidentally diagnosed atrial fibrillation, or with atrial fibrillation identified by systematic ECG screening, will have stroke risk factors that make them eligible for oral anticoagulation.2, 33, 35 Patients with silent atrial fibrillation should also be investigated for concomitant cardiovascular conditions that require therapy.2 Rhythm control therapy is not required in
Management of patients with atrial high-rate episodes identified by implanted devices
All atrial fibrillation therapies have been assessed in patients with ECG-documented atrial fibrillation. Thus, atrial arrhythmias identified by other methods (eg, an irregular pulse detected by blood pressure machines or by an optical device), or atrial high-rate episodes identified by a pacemaker, require verification of atrial fibrillation by ECG before the start of atrial fibrillation therapy.2 Importantly, not all atrial high-rate episodes detected by implanted devices are atrial
Five domains of atrial fibrillation management
Five domains of management are available for atrial fibrillation, in which each treatment component targets different sections of the heart (figure 1). The five domains of atrial fibrillation management are acute stabilisation of patients who present with atrial fibrillation complications or haemodynamic compromise, detection and treatment of underlying and accompanying cardiovascular conditions, stroke risk assessment and oral anticoagulation for stroke prevention, rate control, and rhythm
Cardiovascular examination
The presence of atrial fibrillation strongly indicates that other cardiovascular conditions might exist. To identify such conditions, a careful cardiovascular examination and an echocardiogram should be done in all patients with atrial fibrillation at the time of diagnosis. In young patients with atrial fibrillation, the ECG should be examined for signs of inherited arrhyhthmogenic diseases. Comprehensive diagnosis and treatment of cardiovascular risk factors and concomitant diseases2, 53
Oral anticoagulation for stroke prevention
The combination of a local prothrombotic milieu in the left atrium, systemic activation of coagulation, blood stasis in the atria, and expression of prothrombotic factors on the atrial endothelium all contribute to clot formation and cerebral ischaemia in patients with atrial fibrillation.70, 71, 72 The annual stroke risk in patients with atrial fibrillation without anticoagulation treatment varies between <1% and >10%, depending on stroke risk factors (table 2).71, 72 Oral anticoagulation
Rate control therapy
During atrial fibrillation, each part of the atrial myocardium is stimulated at a rate of 300–400 activations per min. The rapid reactivation of atrial myocardium leads to atrial contractile standstill in most patients and results in rapid and irregular ventricular rates. Most patients with atrial fibrillation who are symptomatic present with high ventricular rates, and control of ventricular rate is used to improve left ventricular function and atrial fibrillation-associated symptoms. Rate
Rhythm control therapy
Restoration and maintenance of sinus rhythm in patients with atrial fibrillation can improve atrial fibrillation-associated symptoms. No evidence suggests that rhythm control therapy improves outcomes in patients with atrial fibrillation. Cardioversion, anti-arrhythmic drugs, and catheter or surgical atrial fibrillation ablation are available for this type of therapy. Current controlled studies such as CABANA (NCT00911508) and EAST-AFNET 4109 will investigate whether modern rhythm control
Integration and stratification of atrial fibrillation management
Implementation of advances in atrial fibrillation management (eg, access to medications that require specialist initiation or interventional and surgical therapy options) is not universal, as shown by the variable use of evidence-based treatments in observational data sets. 13, 16, 17, 77, 142 Furthermore, atrial fibrillation requires chronic management in a large population of patients, including provision of specialist treatment options when needed. Integrated, patient-centred approaches to
Conclusion
Screening for silent atrial fibrillation emerges as an important opportunity to prevent atrial fibrillation-associated complications. All patients with atrial fibrillation should receive long-term treatment in five domains (figure 2): acute haemodynamic stabilisation, detection and treatment of concomitant cardiovascular diseases, assessment of stroke risk and (in most patients) oral anticoagulation, assessment of ventricular rate and (in most patients) rate control therapy, and assessment of
Search strategy and selection criteria
References (171)
- et al.
50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study
Lancet
(2015) - et al.
CHADS2 score and risk of new-onset atrial fibrillation: a nationwide cohort study in Taiwan
Int J Cardiol
(2013) - et al.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Lancet
(2014) - et al.
Drivers of hospitalization for patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF)
Am Heart J
(2014) - et al.
Depressive symptoms predict recurrence of atrial fibrillation after cardioversion
J Psychosom Res
(2007) - et al.
Hypertrophic cardiomyopathy
Lancet
(2013) - et al.
The association between atrial fibrillation and sudden cardiac death: the relevance of heart failure
JACC Heart Fail
(2014) - et al.
Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis
Lancet
(2014) - et al.
Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis
Lancet Neurol
(2015) - et al.
Embolic strokes of undetermined source: the case for a new clinical construct
Lancet Neurol
(2014)
Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): rationale and design of a prospective randomized multicenter study
Am Heart J
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
J Am Coll Cardiol
International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation
Am Heart J
Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis
Lancet
Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study
J Am Coll Cardiol
Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY)
J Am Coll Cardiol
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
Lancet
Stroke prevention in atrial fibrillation
Lancet
Insulin-requiring versus noninsulin-requiring diabetes and thromboembolic risk in patients with atrial fibrillation: PREFER in AF
J Am Coll Cardiol
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation
Chest
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
Lancet
Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke
Am Heart J
Left Atrial Appendage Occlusion Study II (LAAOS II)
Can J Cardiol
Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non-valvular atrial fibrillation
J Thromb Haemost
Oral anticoagulant use in octogenarian European patients with atrial fibrillation: a subanalysis of PREFER in AF
Heart
HRS/NSA 2014 survey of atrial fibrillation and stroke: gaps in knowledge and perspective, opportunities for improvement
Heart Rhythm
Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study
J Thromb Haemost
Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial
Lancet
2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Eur Heart J
Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study
Circulation
Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK
Heart
Estimation of total incremental health care costs in patients with atrial fibrillation in the United States
Circ Cardiovasc Qual Outcomes
Population ages 65 and above (% of total)
DataBank: world development indicators
Global action plan or the prevention and control of noncommunicable diseases 2013–2020
Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation
Ann Intern Med
Causes of death and influencing factors in patients with atrial fibrillation: a competing risk analysis from the randomized evaluation of long-term anticoagulant therapy study
Circulation
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF
Eur Heart J
The registry of the German competence NETwork on atrial fibrillation: patient characteristics and initial management
Europace
Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational research programme-atrial fibrillation general registry pilot phase (EORP-AF pilot registry)
Eur Heart J
Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the prevention of thromboemolic events—European registry in atrial fibrillation (PREFER in AF)
Europace
Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry
Clin Res Cardiol
Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry
Heart
Anxiety sensitivity moderates prognostic importance of rhythm-control versus rate-control strategies in patients with atrial fibrillation and congestive heart failure: insights from the atrial fibrillation and congestive heart failure trial
Circ Heart Fail
Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional comparison of patients enroled in two large clinical trials
Europace
The unrecognized psychosocial factors contributing to bleeding risk in warfarin therapy
Stroke
Depression, anxiety, and quality of life after catheter ablation in patients with paroxysmal atrial fibrillation
Clin Cardiol
Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes
Europace
Effect of dronedarone on cardiovascular events in atrial fibrillation
N Engl J Med
Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study
Stroke
Cited by (124)
Secondary stroke prevention in people with atrial fibrillation: treatments and trials
2024, The Lancet NeurologyLeft Atrial Strain and Incident Atrial Fibrillation in Older Adults
2023, American Journal of CardiologyABCs: A Better Chance to Improve Outcomes in Atrial Fibrillation
2023, JACC: AsiaCase study of OATP1B DDI assessment and challenges in drug discovery and development—real-life examples
2023, Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical ThinkingPerformance of the imPulse device for the detection of atrial fibrillation in hospital settings
2022, Cardiovascular Digital Health Journal